Paul-Peter Tak, Academic Medical Center, University of Amsterdam, The Netherlands (ed): New Therapeutic Targets in Rheumatoid Arthritis. (PIR: Progress in Inflammation Research Series)

Excerpt

New Therapeutic Targets in Rheumatoid Arthritis provides an in depth insight into the role of new and evolving drug therapies for the management of rheumatoid arthritis (RA). The book is well designed, with each chapter dedicated to a specific molecular/cellular target fundamental to the underlying pathophysiology of RA. The book first addresses cellular targets (B and T cells), but then systematically examines cytokine targets (e.g. IL-1, IL-6, IL-15, IL-17, IL-18, oncostatin), chemokines and chemokine receptors, intracellular signalling pathways and epigenetic targets. The early chapters focus on several of the newer but existing biologic therapies (e.g. rituximab, anakinara, tocilizumab, abatacept), whereas the later chapters systematically discuss the potential modes of action and available clinical trial data of evolving drug therapies (e.g. certolizumab and JAK3 inhibitors). The data presented in the book are unbiased, providing information on both therapeutic successes as well as therapeutic interventions with a poor clinical outcomes. …